November 5, 2025 — Leads & Copy — Minerva Neurosciences, Inc. (Nasdaq: NERV) reported business updates and financial results for the third quarter of 2025, ending September 30, 2025.
The company received $80 million in gross proceeds in a private placement on October 23, 2025, before deducting fees and other expenses. The financing includes an initial upfront funding of $80 million and up to an additional $80 million in gross proceeds if all Tranche A warrants are exercised, subject to specified terms and conditions. An additional $40 million may be received if all Tranche B warrants are exercised by cash payment upon achieving the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint.
Minerva Neurosciences Chairman and CEO Dr. Remy Luthringer said the company, strengthened by the recent financing and alignment with the FDA on a confirmatory Phase 3 clinical trial, is on a path forward to advancing roluperidone for the treatment of negative symptoms of schizophrenia. Luthringer anticipates sufficient funds for the Phase 3 study and resubmission of its NDA, as well as preparation for a commercial launch of roluperidone in the US, if approved, despite anticipated increases in R&D, clinical, and administrative expenses.
For the three months ended September 30, 2025, R&D expense was $0.9 million, and G&A expense was $1.9 million. Net loss for the three and nine months ended September 30, 2025, was $2.7 million and $9.8 million, respectively. Cash, cash equivalents, and restricted cash at September 30, 2025, were approximately $12.4 million, compared to $21.5 million at December 31, 2024.
Contact:
Investor inquiries:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.
info@minervaneurosciences.com
Media inquiries:
Helen Shik
Principal
Shik Communications LLC
helen@shikcommunications.com
Source: Minerva Neurosciences
